KR100888466B1 - 혈관형성 억제, 항 종양 및 전 세포사멸 활성을 갖는레티노이드 유도체 - Google Patents

혈관형성 억제, 항 종양 및 전 세포사멸 활성을 갖는레티노이드 유도체 Download PDF

Info

Publication number
KR100888466B1
KR100888466B1 KR1020047001546A KR20047001546A KR100888466B1 KR 100888466 B1 KR100888466 B1 KR 100888466B1 KR 1020047001546 A KR1020047001546 A KR 1020047001546A KR 20047001546 A KR20047001546 A KR 20047001546A KR 100888466 B1 KR100888466 B1 KR 100888466B1
Authority
KR
South Korea
Prior art keywords
compound
tumor
treatment
cells
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047001546A
Other languages
English (en)
Korean (ko)
Other versions
KR20040028968A (ko
Inventor
루시오 멜리니
사브리나 달라발레
세르지오 펜코
기우세페 기안니니
클라우디오 피사노
로레다나 베시
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11455702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100888466(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20040028968A publication Critical patent/KR20040028968A/ko
Application granted granted Critical
Publication of KR100888466B1 publication Critical patent/KR100888466B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
KR1020047001546A 2001-07-31 2002-07-18 혈관형성 억제, 항 종양 및 전 세포사멸 활성을 갖는레티노이드 유도체 Expired - Fee Related KR100888466B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2001A000464 2001-07-31
IT2001RM000464A ITRM20010464A1 (it) 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
PCT/IT2002/000474 WO2003011808A1 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities

Publications (2)

Publication Number Publication Date
KR20040028968A KR20040028968A (ko) 2004-04-03
KR100888466B1 true KR100888466B1 (ko) 2009-03-12

Family

ID=11455702

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047001546A Expired - Fee Related KR100888466B1 (ko) 2001-07-31 2002-07-18 혈관형성 억제, 항 종양 및 전 세포사멸 활성을 갖는레티노이드 유도체

Country Status (19)

Country Link
US (2) US8101793B2 (enExample)
EP (1) EP1412317B1 (enExample)
JP (1) JP4463550B2 (enExample)
KR (1) KR100888466B1 (enExample)
CN (1) CN1279014C (enExample)
AT (1) ATE492526T1 (enExample)
AU (1) AU2002326144B2 (enExample)
BR (1) BR0211521A (enExample)
CA (1) CA2454532C (enExample)
CY (1) CY1114535T1 (enExample)
DE (1) DE60238683D1 (enExample)
DK (1) DK1412317T3 (enExample)
ES (1) ES2358097T3 (enExample)
HU (1) HU229308B1 (enExample)
IT (1) ITRM20010464A1 (enExample)
MX (1) MXPA04000877A (enExample)
PL (1) PL207530B1 (enExample)
PT (1) PT1412317E (enExample)
WO (1) WO2003011808A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
EP1856063B1 (en) 2005-02-22 2012-01-25 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
AU2006233810B2 (en) 2005-04-08 2011-02-17 Galderma Research & Development New method for the preparation of 6-(3-(1-adamantyl)-4-methoxphenyl)-2-naphthoic acid
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
ITRM20050248A1 (it) * 2005-05-20 2006-11-21 Sigma Tau Ind Farmaceuti Uso acido adamantil metossidifenil propenoico per il trattamento di patologie cutanee.
ES2356129T3 (es) * 2005-06-28 2011-04-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivados de ácido bifenil y naftil-fenil hidroxámico.
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2007071605A1 (en) * 2005-12-19 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. The use of st1898 for the treatment of restenosis
JP5054006B2 (ja) * 2006-06-23 2012-10-24 ロート製薬株式会社 ヒアルロン酸産生促進能を有する組成物
WO2008077772A2 (en) * 2006-12-22 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite Spa Combination of a retinoid and a platinum anticancer agent
WO2010000784A1 (en) * 2008-07-03 2010-01-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of restenosis
TW201031402A (en) * 2008-12-24 2010-09-01 Sigma Tau Ind Farmaceuti New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
US9096544B2 (en) 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
PT2758371T (pt) * 2011-09-19 2016-07-13 Sigma Tau Ind Farmaceuti Novos tio derivados que contêm lactamas como potentes inibidores de hdac e suas utilizações enquanto medicamentos
JP5757602B2 (ja) * 2012-05-11 2015-07-29 国立大学法人金沢大学 不斉選択性の切り替えが可能なクロマトグラフィー用充填剤
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
US11707442B2 (en) 2015-09-25 2023-07-25 The General Hospital Corporation Antibacterial and antifungal compounds
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
CN110799182B (zh) * 2017-04-27 2024-02-20 范德比尔特大学 用γ-酮醛清除剂治疗动脉粥样硬化的方法
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
IT201900003343A1 (it) * 2019-03-07 2020-09-07 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
CN111956806B (zh) * 2020-09-03 2023-04-07 四川大学 一种药物载体、胶束、药剂及其制备方法和应用
IT202000029882A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029906A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi.
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
CZ3499A3 (cs) * 1996-07-08 1999-11-17 Galderma Research & Development, S. N. C. Adamantylová sloučenina, její použití a farmaceutický prostředek ji obsahující
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., vol. 32, no. 8, 1989, pp. 1814-1820.

Also Published As

Publication number Publication date
BR0211521A (pt) 2004-09-14
HK1068868A1 (en) 2005-05-06
CA2454532A1 (en) 2003-02-13
CN1279014C (zh) 2006-10-11
PT1412317E (pt) 2011-03-21
AU2002326144B2 (en) 2008-04-10
US20080021088A1 (en) 2008-01-24
ITRM20010464A1 (it) 2003-01-31
ITRM20010464A0 (it) 2001-07-31
KR20040028968A (ko) 2004-04-03
DE60238683D1 (de) 2011-02-03
EP1412317A1 (en) 2004-04-28
MXPA04000877A (es) 2004-06-03
PL207530B1 (pl) 2010-12-31
US20040235757A1 (en) 2004-11-25
US8101793B2 (en) 2012-01-24
DK1412317T3 (da) 2011-03-28
HUP0401604A2 (hu) 2004-12-28
CY1114535T1 (el) 2016-10-05
CN1537094A (zh) 2004-10-13
ATE492526T1 (de) 2011-01-15
CA2454532C (en) 2011-01-25
HUP0401604A3 (en) 2006-01-30
WO2003011808A1 (en) 2003-02-13
ES2358097T3 (es) 2011-05-05
PL368412A1 (en) 2005-03-21
HU229308B1 (en) 2013-10-28
EP1412317B1 (en) 2010-12-22
JP2004536879A (ja) 2004-12-09
JP4463550B2 (ja) 2010-05-19
US7449495B2 (en) 2008-11-11

Similar Documents

Publication Publication Date Title
KR100888466B1 (ko) 혈관형성 억제, 항 종양 및 전 세포사멸 활성을 갖는레티노이드 유도체
AU2002326144A1 (en) Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
JP2763894B2 (ja) 生物学的に活性なカルボン酸エステル類
CN104936591A (zh) 促红细胞生成素表达增强剂
CN114315848A (zh) 胰岛素样生长因子-1受体的小分子抑制剂及其用途
KR20050042044A (ko) 골 이상의 치료를 위한 치료제로서의 알칸 디올 유도체
JPH06192073A (ja) 細胞分化誘導剤
JP2003137894A (ja) アミノアルコールリン酸化合物、製造方法、及びその利用方法
WO2024025953A2 (en) Therapeutic uses of urolithin derivatives
Furuta et al. Designed prostaglandins with neurotrophic activities
JPH0925235A (ja) １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
WO1995032194A1 (en) Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids
US7691900B2 (en) Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics
RS51576B (sr) Bifenil i naftil-fenil derivati hidroksamske kiseline
EP1284263B1 (en) Derivatives of p- hydroxy phenyl propionic acid as antiproliferative agents
KR100903974B1 (ko) 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
JP4431424B2 (ja) 骨形成を促進するための組成物
JP2019218383A (ja) 癌及び心筋梗塞を治療する方法
JP2021534178A (ja) 置換ピラゾール類化合物、その調製方法、医薬組成物及び用途
WO2022105825A1 (en) Compounds as pu. 1 inhibitors
NL8105507A (nl) Nieuwe 16-amino-18,19,20-trinor-prostaglandinederivaten, hun zuuradditiezouten en een werkwijze voor de bereiding ervan.
CN106727460A (zh) Atropurpuran的衍生物组合物用于抗肝纤维化
TW201307311A (zh) 化學合成安卓幸的方法及其抑制非小細胞肺癌的應用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130225

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140224

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150306

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150306